• LAST PRICE
    20.3800
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 20.3800
  • Day Range
    ---
  • 52 Week Range
    Low 13.0000
    High 30.6600
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 18.84
TimeVolumeCINC
09:32 ET47618.56
10:03 ET22818.95
10:06 ET24919.5
10:10 ET45119.94
10:15 ET111419.745
10:17 ET258319.6522
10:19 ET60519.38
10:21 ET120019.66
10:30 ET10019.99
10:32 ET10019.9
10:33 ET20019.93
10:35 ET86720.35
10:37 ET101320.4
10:39 ET82620.6002
10:42 ET10020.7
10:44 ET20020.57
10:46 ET80020.67
10:48 ET80020.2888
10:50 ET10020.2
10:55 ET2446722.27
10:57 ET240921
11:04 ET50020.699
11:06 ET30020.7885
11:08 ET30020.93
11:13 ET60021.04
11:18 ET10021.445
11:20 ET50021.235
11:22 ET60021.35
11:24 ET5370521.25
11:26 ET10020.96
11:27 ET10020.83
11:29 ET140420.695
11:31 ET10020.515
11:33 ET60020.675
11:36 ET223420.5
11:38 ET10020.5
11:44 ET199420.54
11:45 ET270020.61
11:47 ET130020.685
11:49 ET10050020.945
11:51 ET159620.96
11:54 ET94020.88
11:56 ET193020.8105
11:58 ET40020.8
12:02 ET10021
12:05 ET30020.9887
12:09 ET20021.345
12:12 ET20021.02
12:14 ET110020.89
12:16 ET30021
12:18 ET100021.0096
12:20 ET173021.1285
12:21 ET130021.03
12:23 ET63021.09
12:25 ET230021.46
12:32 ET20021.665
12:38 ET50721.94
12:39 ET100021.93
12:41 ET60021.74
12:52 ET30021.9307
12:54 ET211122.03
12:56 ET260021.88
12:57 ET120621.895
12:59 ET10022.01
01:01 ET92221.66
01:08 ET120021.53
01:17 ET10021.64
01:19 ET139121.42
01:35 ET10021.56
01:39 ET30021.445
01:42 ET10021.38
01:44 ET10021.49
01:48 ET30021.37
01:55 ET890021.09
01:57 ET220020.88
02:04 ET30020.85
02:06 ET70021.19
02:08 ET10021.35
02:09 ET60021.38
02:13 ET10021.39
02:15 ET556221.125
02:20 ET90021
02:22 ET10020.96
02:24 ET20021
02:27 ET20020.9706
02:29 ET150020.86
02:31 ET10020.92
02:33 ET10020.9
02:36 ET30020.9
02:38 ET83220.8
02:49 ET140020.75
02:51 ET70720.715
02:54 ET30020.66
02:58 ET10020.4
03:03 ET10020.405
03:05 ET40020.31
03:07 ET30020.26
03:12 ET10020.265
03:16 ET30020.18
03:21 ET70020.53
03:25 ET10020.57
03:27 ET1037720.575
03:30 ET80020.59
03:32 ET67520.46
03:34 ET30020.45
03:36 ET20020.5
03:38 ET50020.47
03:39 ET91520.4
03:41 ET50020.4
03:43 ET40020.26
03:45 ET80020.1898
03:50 ET20020.28
03:52 ET309220.275
03:54 ET123620.25
03:56 ET467320.34
03:57 ET311620.365
03:59 ET1761720.38
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCINC
CinCor Pharma Inc
768.5M
-11.8x
---
United StatesNUVB
Nuvation Bio Inc
767.8M
-8.4x
---
United StatesVERV
Verve Therapeutics Inc
760.6M
-5.5x
---
United StatesIGMS
IGM Biosciences Inc
781.2M
-3.3x
---
United StatesDSGN
Design Therapeutics Inc
786.0M
-18.0x
---
United StatesAVXL
Anavex Life Sciences Corp
797.3M
-17.8x
---
As of 2022-07-05

Company Information

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the target of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In addition to hypertension, the Company is developing CIN-107 for the treatment of primary aldosteronism (PA) and exploring its utility in ameliorating complications of chronic kidney disease (CKD). It also exploring its utility in ameliorating complications of CKD. It is conducting a Phase II clinical trial, which it refers to as its BrigHtn trial.

Contact Information

Headquarters
230 THIRD AVE., 6TH FLOORWALTHAM, MA, United States 02451
Phone
302-658-7581
Fax
302-655-5049

Executives

Independent Director Chairman of the Board
James Healy
Chief Executive Officer, Director
Marc de Garidel
Executive Vice President, Chief Financial Officer and Chief Business Development Officer
Mary Coelho
Chief Operating Officer
Catherine Pearce
Executive Vice President, Clinical Development
Mason Freeman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$768.5M
Revenue (TTM)
$0.00
Shares Outstanding
37.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.72
Book Value
$3.41
P/E Ratio
-11.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.